All In Biotech

NDA 022214 · Astrazeneca

Arimidex

Anastrozole · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 5, 2008 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Dec 5, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

422

120 Phase 3, 66 recruiting

FAERS reports

37,157

25,421 serious, 2,478 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ARIMIDEX · ANASTROZOLE 1MG · TABLET, ORAL · Prescription · TE TBD

Clinical trials

Interventional ClinicalTrials.gov studies with "Anastrozole" as an intervention, any sponsor and status, largest first.

All 422 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue3,541
  • arthralgia3,276
  • nausea2,844
  • alopecia2,620
  • diarrhoea2,441
  • pain1,887
  • headache1,836
  • asthenia1,647
  • dyspnoea1,620
  • dizziness1,571
  • pain in extremity1,461
  • hot flush1,445

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004278
2005385
2006549
20071,232
20081,491
20091,838
20101,308
20111,385
20121,449
2013965
2014994
20151,268
20161,609
20171,936
20182,254
20192,548
20202,234
20212,081
20222,315
20232,611
20242,273
20252,267
20261,886

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Arimidex (Anastrozole)

2024 spending

$3.5M

Beneficiaries

279

1,348 claims

Per beneficiary

$12,683

$50.35 per unit

View as table
YearSpending
2020$5,560,786
2021$4,961,362
2022$4,272,365
2023$3,989,944
2024$3,538,425

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 497 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.